Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient

作者：María Fernanda Landaburu, Gabriela A. López Daneri, Silvia Relloso, Leandro Jorge Zarlenga, Mónica Alejandra Vinante, María Teresa Mujica · 发表于：Revista Argentina de Microbiología · 年份：2019 · DOI：10.1016/j.ram.2019.04.002 · 被引用次数：32 · 研究领域：Clostridium difficile and Clostridium perfringens research、Pharmacological Effects of Natural Compounds、Escherichia coli research studies

The yeast Saccharomyces cerevisiae var. boulardii is a biotherapeutic agent used for the prevention and treatment of several gastrointestinal diseases. We report a case of fungemia in a patient suffering from Clostridiumdifficile-associated diarrhea and treated with metronidazole and a probiotic containing S. cerevisiae var. boulardii. The yeasts isolated from the blood culture and capsules were identified by MALDI-TOF MS and API ID 32 C as S. cerevisiae, and showed the same appearance and color on CHROMAgar Candida. Treatment with fluconazole 400mg/day was initiated and the probiotic was stopped. The patient was discharged from hospital in good condition and was referred to a rehabilitation center. We suggest that the potential benefit of S. cerevisiae var. boulardii should be accurately evaluated, especially in elderly patients. Moreover, all physicians should be trained in the use of probiotic agents and enquire whether the use probiotics was included in the patients'medical histories.